A decision has been issued under the Tennis Anti-Doping Programme (the "Programme") that Adeline Bervoux has committed an Anti-Doping Rule Violation under Article 2.1. That decision imposed a period of ineligibility of two years, commencing on 20 November 2020.
Ms. Bervoux, a 39-year-old wheelchair tennis player from France, provided a urine sample on 24 September 2019 in association with her participation in the French Riviera Open held in Biot, France from 24 September to 28 September 2019 (the “Event”). That sample was sent to the World Anti-Doping Agency (“WADA”) accredited laboratory in Montreal, Canada for analysis, and was found to contain acetazolamide. Acetazolamide is a Specified substance that is prohibited under category S5 of the 2019 WADA Prohibited List (Diuretics and Masking Agents), and therefore is also prohibited under the Programme.
Ms. Bervoux was charged with an Anti-Doping Rule Violation under Article 2.1 of the Programme (presence of a Prohibited Substance in a Player’s Sample) on 5 November 2019. An Independent Tribunal determined that, while there was no evidence that the violation was intentional, Ms. Bervoux could not establish that she bore No Significant Fault or Negligence for her violation. Accordingly the Independent Tribunal found that the period of ineligibility must be two years, the start date of which was back-dated under Programme Article 10.10.3(c) to start on 20 November 2020.
This is Ms. Bervoux’s first Anti-Doping Rule Violation. The decision determines that: (1) Ms. Bervoux has committed a violation of the Programme; (2) she must serve a period of ineligibility of two years; and (3) that period of ineligibility is back-dated to start on 20 November 2020, and so ending at midnight on 19 November 2022. In accordance with Programme articles 9.1 and 10.8, all ranking points and prize money obtained by Ms. Bervoux at the Event and subsequent events are disqualified.